Presumptive treatment strategy for aspergillosis in allogeneic haematopoietic stem cell transplant recipients

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 2, 2007, Pages 350-355

  Oshima, Kumi ^a,b   Kanda, Yoshinobu ^a,b   Asano Mori, Yuki ^c   Nishimoto, Nahoko ^a   Arai, Shunya ^a   Nagai, Sumimasa ^a   Sato, Hiroyuki ^a   Watanabe, Takuro ^a   Hosoya, Noriko ^b   Izutsu, Koji ^a   Asai, Takashi ^a   Hangaishi, Akira ^a   Motokura, Toru ^a   Chiba, Shigeru ^b   Kurokawa, Mineo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c JAPANESE RED CROSS MEDICAL CENTER   (Japan)

Author keywords

Empirical treatment; Febrile neutropenia; Invasive aspergillosis

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B; BUSULFAN; CALCINEURIN INHIBITOR; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUCONAZOLE; FLUDARABINE; MELPHALAN; METHOTREXATE; MICAFUNGIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; THYMOCYTE ANTIBODY; VORICONAZOLE;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CHEMOPROPHYLAXIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROL STRATEGY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENGRAFTMENT; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; INFECTION CONTROL; KIDNEY DYSFUNCTION; LEUKEMIA; LUNG ASPERGILLOSIS; LUNG INFILTRATE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; T CELL DEPLETION; THORAX RADIOGRAPHY; WHOLE BODY RADIATION;

ADULT; AGED; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ENDPOINT DETERMINATION; FEMALE; FLUCONAZOLE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 34547841536     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm217     Document Type: Article

References (30)

1. Brown JMY. Fungal Infection After Hematopietic Stem Cell Transplantation. Third Edition. Cambridge, UK: Cambridge University Press, 2003.
2. Imataki O, Kami M, Kim SW et al. A nationwide survey of deep fungal infections and fungal prophylaxis after hematopoietic stem cell transplantation in Japan. Bone Manrow Transplant 2004; 33: 1173-9.
3. Martino R, Subira M, Rovira. M et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: Incidence and risk factors in 395 patients. Br J Haematol 2002; 116: 475-82.
4. Tollemar J. Fungal Infections. Third Edition. Oxford, UK: Blackwell Publishing Ltd, 2004.
5. Grow WB, Moreb JS, Roque D et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002; 29: 15-9.
6. Wald A, Leisenring W, van Burik JA et al. Epidemiology of Aspergilus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459-66.
7. Baddley JW, Stroud TP, Salzman D et al. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32: 1319-24.
8. Jantunen E, Ruutu P, Niskanen L et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997; 19: 801-8.
9. Petersen FB, Buckner CD, Clift RA et al. Laminar air flow isolation and decontamination: A prospective randomized study of the effects of prophylactic systemic antibiotics in bone marrow transplant patients. Infection 1986; 14: 115-21.
10. Eckmanns T, Ruden H, Gastmeier P. The influence of high-efficiency particulate air filtration on mortality and fungal infection among highly immunosuppressed patients: A systematic review. J Infect Dis 2006; 193: 1408-18.
11. Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-51.
12. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989; 86: 668-72.
13. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-71.
14. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346 225-34.
15. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351 1391-402.
16. Boogaerts M, Winston DJ, Bow EJ et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001; 135: 412-22.
17. Martino R, Viscoli C. Empirical antifungal therapy in patents with neutropenia and persistent or recurrent fever of unknown origin. Br J Haematol 2006; 132: 138-54.
18. Bow EJ. Of yeasts and hyphae: A hematologist's approach to antifungal therapy. Hematology 2006 American Society of Hematology Education Program Book. Washington, DC, USA: American Society of Hematology, 2006; 361-7.
19. Marr KA, Seidel K, Slavin MA et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055-61.
20. Kanda Y, Yamamoto R, Chizuka A et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 2000; 89: 1611-25.
21. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34: 7-14.
22. Kawazu M, Kanda Y, Nannya Y et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1 → 3 -β-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 2004; 42: 2733-41.
23. Gooley TA, Leisenring W, Crowley J et al. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 695-706.
24. Hughes WT, Armstrong D, Bodey GP et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 1997; 25: 551-73.
25. Pizzo PA, Robichaud KJ, Gill FA et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72: 101-11.
26. Kami M, Fukui T, Ogawa S et al. Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis. Clin Infect Dis 2001; 33: 1504-12.
27. Chamilos G, Kontoyiannis DP. Defining the diagnosis of invasive aspergillosis. Med Mycol 2006; 44 Suppl: 163-72.
28. Maertens J, Theunissen K, Verhoef G et al. Ǵalactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: A prospective feasibility study. Clin Infect Dis 2005; 41: 1242-50.
29. Winston DJ, Maziarz RT, Chandrasekar PH et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for longterm antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138: 705-13.
30. Marr KA, Crippa F, Leisenring W et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527-33.